Adverse Events Associated With Aromatase Inhibitors: An Analysis of Real-World Datasets and Drug-Gene Interaction Network

This study analyzed 7,933 adverse event reports related to aromatase inhibitors (AIs) from the FDA Adverse Event Reporting System, covering data from 2004 to 2023. It identified 642 positive signals of adverse reactions, with specific concerns for each AI: anastrozole was linked to antiphospholipid syndrome, plantar fasciitis, and autoimmune pancreatitis; letrozole was associated with androgenetic alopecia, myosclerosis, and pneumonic herpes virus; exemestane was connected to infection reactivation, decreased thyroxine free, and atrial dilatation. Letrozole had the earliest onset of adverse events, followed by exemestane and anastrozole. The study underscores the importance of monitoring these adverse events in real-world clinical settings.